Advertisement

Topics

Search Results for "Where To Buy Pirfenidone"

17:42 EDT 21st October 2017 | BioPortfolio

Matching Channels

None

Matching News

Boehringer Ingelheim Pharmaceuticals, Inc. Release: Results from The INJOURNEY Trial Investigating Ofev With Add-On Pirfenidone Provide New Insights Into This Combination Treatment For IPF

  Life Sciences Jobs   ...

NICE continues to deny patients with early IPF access to pirfenidone

The National Institute for Health and Care Excellence (NICE) has stuck by its recommendation, made last…

Novel fibrosis therapeutics: walking down the TGF-beta pathway

Recent weeks brought startling news of clinical trial successes in the treatment of Idiopathic Pulmonary Fibrosis (IPF). The clinical and commercial consequences have been heavily reviewed elsewhere (...

Boehringer Ingelheim Release: Safety And Efficacy Results From The INJOURNEY Trial Investigating OFEV (Nintedanib) With Add-On Pirfenidone Provide New Data To Support Nintedanib???s Key Role In IPF

  Life Sciences Jobs   ...

Pirfenidone and Nintedanib for Idiopathic Pulmonary Fibrosis

Until recently, there was no effective treatment for idiopathic pulmonary fibrosis, but two new agents were approved in 2014. How do these drugs impact outcomes in this often-fatal disease? Southern...

Immediate-release formulation means fewer pills and more flexibility, says Roche

The European Medicines Agency has approved a new tablet formulation of Esbriet (pirfenidone), which Roche says reduces pill-load and increases dosing flexibility for patients with a rare lung disease.

European Commission approves Roche’s new Esbriet tablet formulation for IPF

The European Commission (EC) has approved a new tablet formulation of Swiss pharmaceutical company Roche’s Esbriet (pirfenidone) to treat patients with mild to moderate idiopathic pulmonary fibrosis...

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Roche today announced results of a six month study combining Esbriet (pirfenidone) and nintedanib treatment, showing a similar safety profile for the combination treatment to that expected for each tr...

Matching PubMed Articles

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.

To analyze the efficacy and adverse events  (AEs) of pirfenidone in idiopathic pulmonary fibrosis (IPF) trials. Methods: MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for studies p...

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis a real-world observational study.

Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of mild-to-moderate disease sever...

Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy.

PurposeThe purpose of the study was to evaluate the efficacy and safety of intravitreal pirfenidone for inhibition of proliferative vitreoretinopathy (PVR) in a model of penetrating ocular injury.Pati...

The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro.

Abstracts Background: Pirfenidone is mostly used in antifibrotic and anti-inflammatory therapies. We have previously demonstrated that pirfenidone had antifibrotic and anti-inflammatory effects on the...

Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.

Pirfenidone is an effective anti-fibrotic agent for idiopathic pulmonary fibrosis (IPF). Although adverse events (AE) sometimes prevent patients from continuing treatment, current dose adjustment guid...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement